Having trouble viewing this email? View it as a Web page.

Change in PDL Status for Intranasal Rhinitis Agents Drug Class, Effective Sept. 29, 2025

Texas Medicaid removed the non-preferred status for certain generic azelastine/fluticasone nasal products on the Texas Preferred Drug List following a drug shortage on brand Dymista products.

Other News

• Columbus Day Holiday to Delay Pharmacy Payments
• HHSC to Participate in Cell and Gene Therapy Access Model
• Temporary Non-preferred Drug Status Begins Sept. 1, 2025

Outreach and Training Reminders

• Pharmacies Must Ensure Contact Information Is Current in PEMS
• Drug Shortage and Expedited Formulary, Preferred Drug List Addition Notification Available
• Texas Health Steps Includes Pharmacy Education Opportunities